Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN will hold an Extraordinary General Meeting of Shareholders (EGM) on December 8, 2025, at the Daejeon Convention Center to vote on the approval of conditional delisting from KOSDAQ and transfer listing to KOSPI. Electronic voting will also be conducted.
📊 [Key Disclosure Details & Major Figures Summary]
- Type of Meeting: Extraordinary General Meeting of Shareholders (EGM)
- Date & Time / Location: December 08, 2025, at 09:00 / 1F Medium Conference Room, Daejeon Convention Center, 107 Expo-ro, Yuseong-gu, Daejeon
- Board Resolution Date: November 06, 2025 (2 Outside Directors attended, Auditor attended)
- Proposed Agenda Items:
- Agenda Item 1: Approval of Conditional Delisting from KOSDAQ Market and Transfer Listing to KOSPI Market
- Agenda Item 2: Change in Limit on Director Remuneration
- Voting Guidelines (Electronic Voting): Pursuant to Article 368-4, Paragraph 1 of the Commercial Act, electronic voting will be made available for shareholders to exercise voting rights without physically attending (Specifics to be announced in the upcoming ‘EGM Convocation Notice’)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of EGM Resolutions and KOSPI Transfer Listing Approval
This disclosure formally announces the convocation of an EGM to table resolutions regarding the transfer listing to KOSPI and changes in director remuneration limits. Confirming whether Agenda Item 1 (conditional delisting from KOSDAQ and transfer listing to KOSPI) is approved as proposed on the EGM date (December 8, 2025) is essential because it allows investors to verify the progress of the market relocation and shareholder decision outcomes. Detailed updates can be cross-checked in subsequent ‘Results of EGM’ disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
